• Something wrong with this record ?

Prediction of the need for phototherapy during hospital stay in preterm infants by transcutaneous bilirubinometry

AA. Raba, A. O'Sullivan, J. Miletin

. 2020 ; 146 (-) : 105029. [pub] 20200520

Language English Country Ireland

Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026653

BACKGROUND: Neonatal hyperbilirubinemia is a common condition that frequently requires treatment with phototherapy and less commonly by exchange transfusion, especially in preterm infants. It is important to identify and monitor infants at risk of severe unconjugated hyperbilirubinemia early in the postnatal period to instigate appropriate management plans. AIMS: To evaluate transcutaneous bilirubinometry (TCB) as a screening tool at 24 and 48 h of age to predict the need for phototherapy during hospital stay in preterm infants. STUDY DESIGN: A single centre prospective cohort study in a level III perinatal centre. SUBJECTS: Preterm infants (23+0 to 36+6 weeks of gestation) were eligible for enrolment. OUTCOME MEASURES: Primary outcome was to assess the predictive value of TCB at 24 and 48 h of age for the need of phototherapy during hospital stay. RESULTS: A total of 338 preterm infants were enrolled. The majority of infants (98.1%) born below 32 weeks of gestation required phototherapy. For infants born at >31 + 6 weeks of gestation, TCB at 24 h of age ≥81 μmol/l had sensitivity 83%, specificity 56%, positive predictive value (PPV) 54.7% and negative predictive value (NPV) 84%. TCB at 48 h of age ≥145 μmol/l had sensitivity 65%, specificity 62%, PPV 24% and NPV 90%. CONCLUSION: TCB performed poorly at 24 and 48 h of age as a predictor of phototherapy during hospital stay in preterm infants. The negative predictive value of the test at 48 h of age might be helpful for infants born after 31 + 6 weeks of gestation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026653
003      
CZ-PrNML
005      
20211026132723.0
007      
ta
008      
211013s2020 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.earlhumdev.2020.105029 $2 doi
035    __
$a (PubMed)32442814
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Raba, Ali Ahmed $u UCD School of Medicine and Medical Sciences, Dublin, Ireland; Coombe Women and Infants University Hospital, Dublin, Ireland
245    10
$a Prediction of the need for phototherapy during hospital stay in preterm infants by transcutaneous bilirubinometry / $c AA. Raba, A. O'Sullivan, J. Miletin
520    9_
$a BACKGROUND: Neonatal hyperbilirubinemia is a common condition that frequently requires treatment with phototherapy and less commonly by exchange transfusion, especially in preterm infants. It is important to identify and monitor infants at risk of severe unconjugated hyperbilirubinemia early in the postnatal period to instigate appropriate management plans. AIMS: To evaluate transcutaneous bilirubinometry (TCB) as a screening tool at 24 and 48 h of age to predict the need for phototherapy during hospital stay in preterm infants. STUDY DESIGN: A single centre prospective cohort study in a level III perinatal centre. SUBJECTS: Preterm infants (23+0 to 36+6 weeks of gestation) were eligible for enrolment. OUTCOME MEASURES: Primary outcome was to assess the predictive value of TCB at 24 and 48 h of age for the need of phototherapy during hospital stay. RESULTS: A total of 338 preterm infants were enrolled. The majority of infants (98.1%) born below 32 weeks of gestation required phototherapy. For infants born at >31 + 6 weeks of gestation, TCB at 24 h of age ≥81 μmol/l had sensitivity 83%, specificity 56%, positive predictive value (PPV) 54.7% and negative predictive value (NPV) 84%. TCB at 48 h of age ≥145 μmol/l had sensitivity 65%, specificity 62%, PPV 24% and NPV 90%. CONCLUSION: TCB performed poorly at 24 and 48 h of age as a predictor of phototherapy during hospital stay in preterm infants. The negative predictive value of the test at 48 h of age might be helpful for infants born after 31 + 6 weeks of gestation.
650    _2
$a dospělí $7 D000328
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a biochemická analýza krve $x přístrojové vybavení $x metody $7 D001774
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a novorozenecká hyperbilirubinemie $x diagnóza $x terapie $7 D051556
650    _2
$a novorozenci extrémně nezralí $7 D062071
650    _2
$a novorozenec $7 D007231
650    _2
$a novorozenec nedonošený $7 D007234
650    _2
$a délka pobytu $7 D007902
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a věk matky $7 D008423
650    _2
$a novorozenecký screening $x metody $7 D015997
650    _2
$a fototerapie $7 D010789
650    _2
$a prospektivní studie $7 D011446
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a O'Sullivan, Anne $u Coombe Women and Infants University Hospital, Dublin, Ireland
700    1_
$a Miletin, Jan $u UCD School of Medicine and Medical Sciences, Dublin, Ireland; Coombe Women and Infants University Hospital, Dublin, Ireland; Institute for the Care of Mother and Child, Prague, Czech Republic; 3rd School of Medicine, Charles University, Prague, Czech Republic. Electronic address: miletinj@yahoo.com
773    0_
$w MED00001465 $t Early human development $x 1872-6232 $g Roč. 146, č. - (2020), s. 105029
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32442814 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132729 $b ABA008
999    __
$a ok $b bmc $g 1715402 $s 1147160
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 146 $c - $d 105029 $e 20200520 $i 1872-6232 $m Early human development $n Early Hum Dev $x MED00001465
LZP    __
$a Pubmed-20211013
Back

Find record

Citation metrics

Logged in users only

Archiving options